Novo Nordisk, Eli Lilly & Co. and Sanofi dominate the market for insulin products worldwide, while the much-smaller Biocon is a key player in the copycat segment. The global insulin-pen market is ...

Novo Nordisk has decided that it wants its own triple agonist, and is willing to hand over $200 million upfront to United Laboratories’ subsidiary United Biotechnology. In return for the global ...

Novo Nordisk has been drafting a number of nonexclusive partnerships for its as-yet unlaunched pen offering. When it first announced the product, it already had partnerships in place with with Dexcom, ...